PMV Pharmaceuticals
PMVP
120 hedge funds and large institutions have $614M invested in PMV Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 43 increasing their positions, 32 reducing their positions, and 10 closing their positions.
150% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 10
52% more call options, than puts
Call options by funds: $558K | Put options by funds: $366K
34% more repeat investments, than reductions
Existing positions increased: 43 | Existing positions reduced: 32
14% more funds holding
Funds holding: 105 → 120 (+15)
6.61% less ownership
Funds ownership: 134.13% → 127.52% (-6.6%)
21% less capital invested
Capital invested by funds: $775M → $614M (-$161M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$6.2M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
+$4.65M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
+$3.28M |
| 4 |
MPAM
Monarch Partners Asset Management
Boston,
Massachusetts
|
+$3.04M |
| 5 |
Millennium Management
New York
|
+$2.32M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$25.6M |
| 2 |
State Street
Boston,
Massachusetts
|
-$18.4M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$6.37M |
| 4 |
PHS
PFM Health Sciences
San Francisco,
California
|
-$5.19M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
-$4.84M |
PMVP Hedge Fund Activity: Q3 2022 in Review
120 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in PMV Pharmaceuticals (PMVP) for Q3 2022, worth a combined $614M — down 21% from $775M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new PMVP positions and 10 closed out — a net gain of 15 holders — while 43 added to existing stakes and 32 trimmed.
The largest buyer was Woodline Partners, adding an estimated $6.2M. The largest seller was Morgan Stanley, cutting an estimated $25.6M.
- 120 institutional investors held PMV Pharmaceuticals (PMVP) as of Q3 2022, up from 105 in Q2 2022.
- Funds reported $614M of PMV Pharmaceuticals stock for Q3 2022, down 21% quarter-over-quarter.
- 25 funds opened new PMV Pharmaceuticals positions in Q3 2022 and 10 closed out, a net change of +15 holders.
- The largest PMV Pharmaceuticals buyer in Q3 2022 was Woodline Partners, an estimated $6.2M added.
- The largest PMV Pharmaceuticals seller in Q3 2022 was Morgan Stanley, an estimated $25.6M sold.
Based on aggregated 13F filings for Q3 2022.